AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 151 min read

UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating

UBS raised its price target for uniQure to $48 from $27 and maintained a buy rating. The stock has seen a 5-day change of 21.98 USD, a 1st Jan change of +4.79%, and a year-to-date change of -8.65%.

Original reporting
marketscreener.com
Published Oct 15, 2026, 3:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 3:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$QURE
Relevance
6/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade may prompt short‑term buying, but the effect depends on broader market sentiment toward biotech.

02

Market read

Analyst target change is a modest catalyst for UniQure, offering a short‑term trading idea.

03

What to watch

Potential regulatory or trial setbacks not reflected in the analyst's target.

Relevance 6/10Novelty 5/10Timing: today

Background

UBS provides price target updates as part of its equity research coverage. The new target reflects revised valuation assumptions.

Market effects

Sector

May lift sentiment in the gene‑therapy/biotech sector as peers could be re‑rated.

Regional

Limited to U.S. biotech investors; no broad market effect.

Global

Minimal global impact beyond UniQure and its immediate peers.

Counterpoint

What could challenge this read

The target raise could be premature if upcoming trial data disappoint, leading to a pull‑back.

Key entities

  • company
    UniQure

    Gene‑therapy developer listed on NASDAQ.

  • analyst
    UBS

    Investment bank issuing the price target revision.

Read at source← All news

Related articles

OCT 7
$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

simplywall.st3 min
OCT 5
Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

marketscreener.com1 min
OCT 2
$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.

investing.com2 min